Literature DB >> 28868622

Proliferation inhibition of cisplatin-resistant ovarian cancer cells using drugs screened by integrating a metabolic model and transcriptomic data.

E Motamedian1, E Taheri1, F Bagheri1.   

Abstract

OBJECTIVES: If screening to find effective drugs is possible, the inhibition of proliferation using existing drugs can be a practical strategy to control the drug resistance of cancer. Development of a system-oriented strategy to find effective drugs was the main aim of this research.
MATERIALS AND METHODS: An algorithm (transcriptional regulated flux balance analysis [TRFBA]) integrating a generic human metabolic model with transcriptomic data was used to identify genes affecting the growth of drug-resistant cancer cells. Drugs that inhibit activation of the target genes were found and their effect on the proliferation was experimentally evaluated.
RESULTS: Experimental assessments demonstrated that TRFBA improves the prediction of cancer cell growth in comparison with previous algorithms. The algorithm was then used to propose the system-oriented strategy to search drugs effective in limiting the growth rate of the cisplatin-resistant A2780 epithelial ovarian cancer cell. Experimental evaluations resulted in the selection of azathioprine, terbinafine, hydralazine and sodium valproate that appropriately inhibit the proliferation of resistant cancer cells while minimally affecting normal cells. Furthermore, experimental data indicate that the selected drugs are synergistic and can be used in combination therapies.
CONCLUSIONS: The proposed strategy was successful to identify drugs effective on the viability of resistant cancer cells. This strategy can enhance the potency of treatments for drug-resistant cancer cells and provides the possibility of using existing drugs.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28868622      PMCID: PMC6529125          DOI: 10.1111/cpr.12370

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  36 in total

Review 1.  Metabolic network modeling and simulation for drug targeting and discovery.

Authors:  Hyun Uk Kim; Seung Bum Sohn; Sang Yup Lee
Journal:  Biotechnol J       Date:  2011-11-29       Impact factor: 4.677

2.  Reconstruction and validation of a constraint-based metabolic network model for bone marrow-derived mesenchymal stem cells.

Authors:  H Fouladiha; S-A Marashi; M A Shokrgozar
Journal:  Cell Prolif       Date:  2015-07-01       Impact factor: 6.831

3.  Terbinafine inhibits oral squamous cell carcinoma growth through anti-cancer cell proliferation and anti-angiogenesis.

Authors:  Ming-Hsien Chien; Tong-Sheng Lee; Chieh Kao; Shun-Fa Yang; Wen-Sen Lee
Journal:  Mol Carcinog       Date:  2011-05-11       Impact factor: 4.784

4.  Characterization of a novel metabolic strategy used by drug-resistant tumor cells.

Authors:  Mary-Ellen Harper; Andreas Antoniou; Elizabeth Villalobos-Menuey; Alicia Russo; Richard Trauger; Minda Vendemelio; Amanda George; Richard Bartholomew; Dennis Carlo; Azhar Shaikh; Jami Kupperman; Evan W Newell; Ivan A Bespalov; Susan S Wallace; Ye Liu; Jeffrey R Rogers; Gregory L Gibbs; Jack L Leahy; Robert E Camley; Robert Melamede; M Karen Newell
Journal:  FASEB J       Date:  2002-10       Impact factor: 5.191

5.  Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.

Authors:  David W Chan; Vincent W S Liu; George S W Tsao; Kwok-Ming Yao; Toru Furukawa; Karen K L Chan; Hextan Y S Ngan
Journal:  Carcinogenesis       Date:  2008-07-16       Impact factor: 4.944

6.  Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity.

Authors:  Steven J Kridel; Fumiko Axelrod; Natasha Rozenkrantz; Jeffrey W Smith
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

7.  In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53-associated cell cycle arrest.

Authors:  Wen-Sen Lee; Rong-Jane Chen; Ying-Jan Wang; How Tseng; Jiiang-Huei Jeng; Shyr-Yi Lin; Yu-Chih Liang; Chien-Ho Chen; Chien-Huang Lin; Jen-Kun Lin; Pei-Yin Ho; Jan-Show Chu; Wei-Lu Ho; Li-Ching Chen; Yuan-Soon Ho
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

8.  Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer.

Authors:  Giuseppe Facchetti; Mattia Zampieri; Claudio Altafini
Journal:  BMC Syst Biol       Date:  2012-08-29

9.  Context-specific metabolic networks are consistent with experiments.

Authors:  Scott A Becker; Bernhard O Palsson
Journal:  PLoS Comput Biol       Date:  2008-05-16       Impact factor: 4.475

10.  Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling.

Authors:  Rasmus Agren; Adil Mardinoglu; Anna Asplund; Caroline Kampf; Mathias Uhlen; Jens Nielsen
Journal:  Mol Syst Biol       Date:  2014-03-19       Impact factor: 11.429

View more
  5 in total

1.  Terbinafine prevents colorectal cancer growth by inducing dNTP starvation and reducing immune suppression.

Authors:  Li-Peng Hu; Wuqing Huang; Xu Wang; Chunjie Xu; Wei-Ting Qin; Dongxue Li; Guangang Tian; Qing Li; Yaoqi Zhou; Suyuan Chen; Hui-Zhen Nie; Yujun Hao; Jian Song; Xue-Li Zhang; Jan Sundquist; Kristina Sundquist; Jun Li; Shu-Heng Jiang; Zhi-Gang Zhang; Jianguang Ji
Journal:  Mol Ther       Date:  2022-06-27       Impact factor: 12.910

2.  Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma.

Authors:  Xing Xu; Jun Chen; Yan Li; Xiaojie Yang; Qing Wang; Yanjun Wen; Ming Yan; Jianjun Zhang; Qin Xu; Yan Wei; Wantao Chen; Xu Wang
Journal:  Cell Death Dis       Date:  2021-05-13       Impact factor: 8.469

3.  Molecular characterization of breast cancer cell response to metabolic drugs.

Authors:  Lucía Trilla-Fuertes; Angelo Gámez-Pozo; Jorge M Arevalillo; Mariana Díaz-Almirón; Guillermo Prado-Vázquez; Andrea Zapater-Moros; Hilario Navarro; Rosa Aras-López; Irene Dapía; Rocío López-Vacas; Paolo Nanni; Sara Llorente-Armijo; Pedro Arias; Alberto M Borobia; Paloma Maín; Jaime Feliú; Enrique Espinosa; Juan Ángel Fresno Vara
Journal:  Oncotarget       Date:  2018-01-08

4.  SLC6A8 Knockdown Suppresses the Invasion and Migration of Human Hepatocellular Carcinoma Huh-7 and Hep3B Cells.

Authors:  Lu Yuan; Xian Jian Wu; Wen Chuan Li; Chenyi Zhuo; ZuoMing Xu; Chuan Tan; RiHai Ma; JianChu Wang; Jian Pu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

5.  Bipolar Disorder Treatments and Ovarian Cancer: A Systematic Review.

Authors:  Mario Miniati; Ciro Conversano; Laura Palagini; Beatrice Buccianelli; Mariagrazia Fabrini; Maricia Mancino; Concetta Laliscia; Donatella Marazziti; Fabiola Paiar; Angelo Gemignani
Journal:  Clin Neuropsychiatry       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.